Related Experiment Video
Updated: Jun 21, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation
M R Benfield1, S Bartosh, D Ikle
1Division of Pediatric Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. Benfield@uab.edu
Insights
Steroid withdrawal after pediatric transplantation, using a specific immunosuppression regimen, improved allograft survival but increased complications. This approach is not recommended for routine pediatric use due to safety concerns.
Area of Science:
- Pediatric Transplantation Immunology
- Immunosuppressive Therapy
Background:
- Steroids are a cornerstone of immunosuppression post-transplantation, but associated with significant side effects in pediatric patients.
- Hypothesis: Robust early immunosuppression could permit safe steroid withdrawal, reducing complications and improving outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of early steroid withdrawal in pediatric transplant recipients.
- To assess the impact on allograft survival, rejection rates, growth, and complications.
Main Methods:
- 274 pediatric subjects received anti-CD25 antibody, sirolimus, calcineurin inhibitor, and steroids.
- At 6 months, subjects were randomized to steroid withdrawal (n=73) or continued low-dose steroids (n=59).
- Study terminated early due to post-transplant lymphoproliferative disorder incidence.
Main Results:
- No difference in standardized height z-score at 18 months; greater height velocity in steroid withdrawal group (p=0.033).
- No difference in acute rejection episodes between groups.
- Significantly higher 3-year allograft survival in steroid withdrawal group (98.6%) vs. control (84.5%) (p=0.002).
Conclusions:
- The immunosuppressive protocol allowed steroid withdrawal without increasing rejection or allograft loss.
- However, the high incidence of complications, including post-transplant lymphoproliferative disorder, precludes recommendation for routine pediatric use.
Abstract:
In an effort to reduce rejection, extend allograft survival and minimize complications, we hypothesized that robust immunosuppression during the first 6 months after transplantation would allow for the safe withdrawal of steroids. A total of 274 pediatric subjects were enrolled and received an anti-CD25 antibody, sirolimus, calcineurin inhibitor and steroids. At 6 months after transplantation, subjects were randomized to steroid withdrawal (n=73) versus continued low-dose steroids (n=59). This study was stopped prior to target enrollment because of the incidence of post-transplant lymphoproliferative disorder. At the time of study termination, 132 subjects had been randomized and were available for analysis. At 18 months after transplantation, there was no difference in the standardized height z score; however, the standardized height velocity was greater in the steroid withdrawal group compared to the control group (p=0.033). There were no differences in acute rejection episodes between treatment groups. The 3-year allograft survival rate was 84.5% in the control group and 98.6% in the steroid withdrawal group (p=0.002). The immunosuppressive protocol utilized in this study allowed for the withdrawal of steroids without an increased risk of rejection or allograft loss. However, the complications associated with the use of this immunosuppressive protocol were too high to recommend its routine use in pediatric patients.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Pharmacokinetics in Pediatric Patients: Drug Excretion